Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer

Fig. 4

Drug combinations induce caspase-dependent apoptosis and G2/M phase and regulate cell cycle regulatory molecules: A Caspase-3/7 activity in SW13 and NCI-H295R cells treated with OTS167, RGB-286638, and OTS167 and RGB-286638 combined, analyzed by Caspase-Glo 3/7 assay. B Expression of cleaved caspase-3 in SW13 (left panel) and NCI-H295R (right panel) cells treated with OTS167, RGB-286638, and OTS167 and RGB-286638 combined, analyzed by Western blot analysis. C SW13 and NCI-H295R cells were treated for 24–48 h and 48–72 h, respectively. Cell cycles were analyzed with PI staining. Bar graphs represent the percentage (%) of cells in G2/M, S, and G1 phase in SW13 (left panel) and NCI-H295R (right panel) cells. D Expression of Cyclin A2, Cyclin B1 and Cyclin B2 in SW13 and NCI-H295R cells treated with OTS167, RGB-286638, and OTS167 and RGB-286638 combined. E Expression of p21Cip1 and p27Kip1 in SW13 cells (left panel) treated for 24–48 h and NCI-H295R cells (right panel) treated for 48–72 h with OTS167, RGB-286638, and OTS167 and RGB-286638 combined

Back to article page